Navigation Links
Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
Date:9/30/2010

EAST BRUNSWICK, N.J., Sept. 30 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the United States District Court for the Southern District of New York has dismissed the Class Action originally filed on November 25, 2008, and captioned Richard Sagall vs. Savient Pharmaceuticals, Inc., et al., against the Company and two of its former officers. The suit alleged that the Company made false and misleading statements relating to the GOUT1 and GOUT2 phase 3 clinical trials and that the Company failed to disclose in a timely manner serious adverse events which occurred in five patients in these trials. The Company and the other named defendants had filed a motion to dismiss the complaint in June 2009.

The Court's decision dismissing the Class Action is based on the plaintiff's failure to set forth particularized facts, through direct or circumstantial evidence, which give rise to a strong inference that the defendants acted with intent to defraud, recklessness or a conscious disregard of the truth. The Court also concluded that the plaintiff had not demonstrated that there was any evidence that the defendants engaged in conscious misbehavior or recklessness in the manner it disclosed the relevant clinical trials data, and that the plaintiff failed to show that the defendants had made false and misleading statements or material omissions in its statements to the detriment of the investing public. The Court's ruling, while dismissing all claims, does not preclude the plaintiff from seeking to file an amended complaint, and is also subject to appeal.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient also manufactures and suppl
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has ... a Phase 3 study for inherited retinal dystrophies caused by mutations ... Marrazzo , is presenting this and other corporate updates today, at ... Francisco . Marrazzo said Spark was able to achieve its ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Accuray Incorporated (Nasdaq: ARAY ), the premier ... investor meeting on Monday, October 3, at the annual meeting ... Beach, Florida. The meeting is open to institutional investors and ... meeting, beginning at 7:00 a.m. E.D.T. on Monday, October 3 ...
... 25, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... on hospital acute care and gastroenterology markets, today announced ... Stifel Nicolaus 2011 Healthcare Conference at the Four Seasons ... a.m. Eastern Time. The presentation will be ...
Cached Medicine Technology:Accuray Incorporated to Host Investor Meeting at ASTRO 2011 2
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... the potential to ward off depression among retirees, particularly ... online in The Journals of Gerontology, Series ... the article " Internet Use and Depression Among Retired ... ," the authors report that Internet use reduced the ... their study sample. , Late-life depression affects between ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... 12-to-1 Return on Investment, MINNEAPOLIS, March 21 ... Therapy Management (MTM) as a benefit option,to employer ... published in the,Journal of the American Pharmacists Association ... MTM services through improved health,outcomes and lower total ...
... A CI head once noted that,"Competitive Intelligence is like ... you realize you need it is when it is ... companies need competitive,intelligence to effectively deal with a turbulent ... that people begin to realize how,critical competitive intelligence is ...
... in Stopping Deadly High-Pressure Bleeding, BETHESDA, Md., ... Research (ISR), the world,s premier ballistic injury research,facility, ... that TraumaCure,s,ground- breaking product, WoundStat(TM), is the most ... the number one cause of,death for soldiers in ...
... Inc. (OTC,Bulletin Board: RXEI), a developer, manufacturer, ... today announced the signing of a,multi-source contract ... of RxElite,s,anesthetic gas products, Sevoflurane and Isoflurane. ... all classes of trade and the,company,s anesthetic ...
... biomarkers for diabetes, heart disease than in males , , ... damage to their cardiovascular health from poor sleep than ... believe they,ve determined why. , They found that ... higher levels of biomarkers associated with increased risk of ...
... in Three Categories: Sustainable Technology, Life Sciences, ... ... winners of the 2008 McGinnis,Venture Competition, which awarded more than $140,000 ... of Business at,Carnegie Mellon University, Yale University and the University of ...
Cached Medicine News:Health News:ClearScript Offers Innovative Medication Therapy Management Program to Employee Health Plans 2Health News:New Research Uncovers How to Build and Maintain an Effective Competitive Intelligence Group 2Health News:U.S. Army Study Reports WoundStat(TM) is Most Effective 2Health News:U.S. Army Study Reports WoundStat(TM) is Most Effective 3Health News:RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites 2Health News:RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites 3Health News:Lack of Sleep Hurts Women's Hearts Most 2Health News:Teams From Carnegie Mellon, Yale, Manitoba Win Tepper School's 2008 McGinnis Venture Competition 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: